Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:03:22.037Z.
Calculation as of: 2026-10-06T21:03:22.037Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24b9ae44b863bde1b5ff94dee696d3b0f0fe2fcb905e2d2ce235618745c02026
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$32.93M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scilex Holding Company (SCLX) | $33.63M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.35M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $32.79M | 17.64x | 36.10x | 319.62x | 319.62x |
| HeartBeam, Inc. (BEAT)vs › | $32.42M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | N/A | N/A | N/A | N/A |
| Nortech Systems Incorporated (NSYS)vs › | $31.52M | 19.09x | 29.28x | 15.24x | 15.09x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
